|Year : 2016 | Volume
| Issue : 3 | Page : 343-347
Is hemoglobin A1c level effective in predicting the prognosis of Fournier gangrene?
Haluk Sen1, Omer Bayrak1, Sakip Erturhan1, Ersin Borazan2, Mustafa Nihat Koc3
1 Department of Urology, Gaziantep University, Gaziantep, Turkey
2 Department of General Surgery, Gaziantep University, Gaziantep, Turkey
3 Department of Plastic and Reconstructive Surgery, Gaziantep University, Gaziantep, Turkey
|Date of Submission||07-May-2015|
|Date of Acceptance||05-Aug-2015|
|Date of Web Publication||29-Jun-2016|
Department of Urology, University of Gaziantep, School of Medicine, Gaziantep 27310
| Abstract|| |
Objectives: To evaluate the effect of immune failure and/or diabetes mellitus (DM) association on the mortality and morbidity of the Fournier's Gangrene (FG), and interrelatedly, the usability of HbA1c level in the prediction of prognosis.
Materials and Methods: The data of 38 patients with the diagnosis of FG were investigated retrospectively. The patients were divided into two groups as patients with DM (Group 1, n = 18) and non-diabetics (Group 2, n = 20). The patients in group 1 were also divided into two subgroups as patients with HbA1c value ≥7 (Group 1a) and HbA1c value <7 (Group 1b).
Results: The mean age of all 38 male patients was 66.3 ± 6.4 years. The initial symptoms were scrotal rash and swelling (n = 20, 52.6%), high fever (>38°C) (n = 22, 57.8%), purulent discharge from genital or perineal areas (n = 13, 34.2%), skin bruises (n = 11, 28.9%) and general state disorder in five patients that were admitted from day care center (13.1%). DM, as the most often comorbid disease, was detected in 18 patients (47.3%). Six patients (15.7%) were deceased during the follow-up period.
Conclusion: In the present study, the researchers determined that diabetic patients with HbA1c level of 7 or higher had worse prognosis, and increased mortality.
Keywords: Diabetes mellitus, Fourniere's gangrene, hemoglobin A1c
|How to cite this article:|
Sen H, Bayrak O, Erturhan S, Borazan E, Koc MN. Is hemoglobin A1c level effective in predicting the prognosis of Fournier gangrene?. Urol Ann 2016;8:343-7
|How to cite this URL:|
Sen H, Bayrak O, Erturhan S, Borazan E, Koc MN. Is hemoglobin A1c level effective in predicting the prognosis of Fournier gangrene?. Urol Ann [serial online] 2016 [cited 2019 Oct 16];8:343-7. Available from: http://www.urologyannals.com/text.asp?2016/8/3/343/184905
| Introduction|| |
Fournier gangrene (FG) is the sudden and rapidly progressive necrotizing fasciitis of the fascias in genital, perineal and perianal areas. Following its onset, it can progress upward in the facial plane, and spread to the abdomen wall. The incidence of the disease is 1.6/100.000 in males, and its peak incidence occurs in the fifth and sixth decade. The male/female ratio is approximately 10/1.
Effective pathogens taking part in FG etiology are generally skin, genitourinary, and gastrointestinal-derived polymicrobial anaerobic and aerobic microorganisms and they can be identified in 95% of the cases. Pathogens that are often isolated from wound site cultures are Escherichia More Details coli, Streptococcus, Staphylococcus, Enterococcus, and Bacteroides species. Methicillin-resistant and Candida species can also be isolated from the patients who are hospitalized for a long period of time. Bacterial infection leads to thrombosis in small subcutaneous veins, and thus creates a suitable condition for the growth of anaerobic microorganisms by lowering the amount of the oxygen in the tissue during the development process of the disease. The presence of the diabetic microangiopathy makes this situation worse. On the other hand, the enzymes such as collagenase, heparinase, hyaluronidase, streptokinase, and streptodornase, which are produced by either anaerobic or aerobic microorganisms, accelerate the tissue breakdown and cause rapid progress by disrupting the vascularity.
In the present study, the demographic and clinical data, and the treatments of the patients who were admitted to the Urology Department in the last 5 years were investigated retrospectively. The study aimed to investigate the effect of immune failure and/or diabetes mellitus (DM) association on the mortality and morbidity of the disease, and inter-relatedly, the usability of hemoglobin A1c (HbA1c) level in the prediction of disease prognosis in this patient group.
| Materials and Methods|| |
The data of 38 patients who were admitted to Gaziantep University Medical Faculty Urology Clinic between January 2008 and July 2013 with the diagnosis of FG were investigated retrospectively. The patients were divided into two groups as patients with DM (Group 1, n = 18) and nondiabetics (Group 2, n = 20). The patients in Group 1 were also divided into two subgroups as patients with HbA1c value ≥7 (Group 1a) and HbA1c value <7 (Group 1b).
The time period between the onset of the first symptoms and the time of admission was set at the first admission time. All patients underwent systemic and urological physical examination following their medical history during their initial evaluation. The patients who were monitored for vital findings (temperature, heart rate, respiratory rate, and arterial blood pressure) were hospitalized. Considering the possible etiology, consultation was requested from relevant departments including general surgery, endocrinology, cardiology, and gastroenterology. Routine laboratory tests (serum urea, creatinine, sodium, potassium, calcium, chloride, alanine transaminase, aspartate aminotransferase, whole blood count, sedimentation, and C-reactive protein level), arterial blood gas analyses, urine analysis, urine culture, blood cultures and when needed, radiological imaging were requested.
All patients were administered with empirical parenteral ceftriaxone (2 g/day), gentamicin (160 mg/day) or netilmicin (appropriate doses, according to level of creatinine) and ornidazole (1 g/day). Medical treatments of patients were readjusted in one of the following conditions: (1) Who had no recovery in their clinical or laboratory values within the first 48 h, (2) Who did not respond to empirical treatment, or (3) Growth of different types of microorganisms in cultures. Debridement under general anesthesia was performed for all patients, and multiple wound cultures from the collected tissues were sent for analysis. Urethral catheters or suprapubic catheter was used for urine drainage. During the postoperative early period, total parenteral nutrition and blood transfusion (when needed) were performed to provide calorie support.
Depending on the lesion extensity, wound debridement was performed once or twice per day. Debridement procedures were carried out within the intervention room in the urology service. Fentanyl (1–2 µg/kg) and/or midazolam (1 mg) intravenous (IV) was used as sedo-analgesics. Following the resection of necrotic tissues, wound sites were rinsed with povidone iodine and were closed with gauze containing 0.5% chlorhexidine acetate BP (Bactigras ®). During the follow-up, the lesion was closed primarily (whenever possible), if the patient's wound site infection were recovered. In the case of wider lesions, split-thickness graft application was performed by the Department of Plastic and Reconstructive Surgery.
For each patient, Founier's Gangrene Severity Index (FGSI) that was defined by Laor et al. and modified body surface area, nomogram were calculated to demonstrate the disease extent [Table 1]. In addition to the parameters within the index, the researchers also analyzed the HbA1c levels in DM patients. In addition, the effective pathogens in tissue cultures were recorded, and the growth ≥105 colonies were considered significant.
SPSS windows version 11.5 (SPSS, Chicago, IL) was used for the analysis and P values lower than 0.05 were accepted as significant. Mann–Whitney U-test was used to compare the two independent groups, and the relationship between the categorical variables was tested by Chi-square analysis.
| Results|| |
The mean age of all 38 male patients was 66.3 ± 6.4 years. The initial symptoms were scrotal rash and swelling (n = 20, 52.6%), high fever (>38°C) (n = 22, 57.8%), purulent discharge from genital or perineal areas (n = 13, 34.2%), skin bruises (n = 11, 28.9%), and general state disorder in 5 patients that were admitted from day care center (13.1%). DM, as the most often comorbid disease, was detected in 18 patients (47.3%). The other comorbid diseases were presented in [Table 2]. The underlying etiological factors were presented in [Table 3]. There was no etiological factor in 10 patients (26.3%); however, these patients had bad self-care. The effective pathogens were presented in [Table 4]. Accordingly, E. coli was the most frequently isolated microorganism in both groups. When the clinical and laboratory values in Group 1 patients were compared to Group 2 patients, Group 1 had statistically significant mean age, shorter first admission time (as the disease progressed faster), longer hospitalization time, higher lesion width, and higher FGSI scores [Table 5]. Within Group 1 patients, patients in Group 1a had longer hospitalization times, broader lesion area, and higher FGSI scores compared to the patients in Group 1b [Table 6]. Six patients (15.7%) were deceased during the follow-up period. Most of these patients were in Group 1a (n = 4) while 1 patient was in Group 1b, and 1 was in Group 2. FGSI scores were significantly higher in the deceased patients (15.2 ± 3.3 vs. 5.2 ± 1.6, P < 0.0001).
|Table 3: Bacterial organisms isolated from wound cultures of patients with FG|
Click here to view
| Discussion|| |
The key to success in the treatment of FG is the early and aggressive debridement of the necrotized tissue., The mortality rate may reach to 88% despite this aggressive treatment. Immune suppression diseases such as DM with vascular damage, chronic alcohol consumption, HIV infection, cardiac disorders, systemic lupus erythematosus, renal failure, and trauma can be regarded as predisposing factors. The mortality rate of FG is high, and the range is between 20% and 50% despite the recent developments.,
Criteria for determining mortality have been investigated and among these; the correlation between advanced age, primary anorectal infections, presence of DM, sepsis, delayed treatment, width and depth of involvement, low level of hematocrite, high leukocyte count, BUN, alkaline phosphotase and albumin levels, and prognosis has been studied.,,,, On the other hand, there are some studies which indicate that the disease dissemination is the most important factor affecting the disease progression, as it reflects the status of the patient's immune system.,
In 1995, Loar et al. developed FGSI in order to evaluate the severity of the disease. A total of nine parameters were defined in this index, and the degree of deviation from normal was graded from 0 and 4 [Table 1]. Again in the same study, the authors reported that the mortality risk was 75%, if the FGSI score is >9, and 78%, if the FGSI score is <9. In some of the following studies, FGSI has been shown to be used to predict the disease prognosis and mortality. In their 27 patient-series, Ulug et al. found that FGSI scores were 5.04 ± 2.49 and 13.6 ± 4.6 in surviving patients and deceased patients, respectively (P < 0.0001).
 In the retrospective study by Yeniyol et al. on 25 patients, the authors found that FGSI levels were 3.0 ± 1.8 and 12 ± 2.4 in surviving patients and deceased patients, respectively.
 On the other hand, in their 20 patient-series, Tuncel et al. defended that FGSI could not be used to predict the mortality and that predisposing factors and the length of the lesions were more important criteria.
In our study, FGSI levels were found to be statistically significant as 14.9 ± 2.3 and 5.5 ± 2.1 in Group 1 and Group 2, respectively (P = 0.001). Similarly, FGSI scores were significantly higher in deceased patients compared to surviving patients (15.2 ± 3.3 vs. 5.2 ± 1.6, P < 0.0001).
DM, a metabolical disease, has been long recognized as a risk factor for FG, and is seen in 10–60% of DM patients. Deterioration in chemotaxis, phagocytosis, and cellular digestion functions are seen in DM, which in turn increases the predisposition to infections. Tuncel et al. carried out a study on 20 FG patients and found that 66% of the deceased patients had DM, thus reporting that DM might be a major predisposing factor. HbA1c, which reflects the mean glycemic control of the past few months, is a very common laboratory test to predict the diabetes-associated complications in DM patients.,
In the present study, 4 patients in Group 1 required mechanical ventilator support, and these patients were deceased in the surgical Intensive Care Unit. At the same time, three of these 4 patients had HbA1c levels of 7 or higher. Hospitalization time was longer in DM patients (22.5 ± 6.8 days) compared to nondiabetic patients (19 ± 4.8 days) (P = 0.03).
Perineal infections are the most common cause of infections in FG. However, in their 1726 FG patient-series, Eke  reported that the infection foci was the skin in 24% of the patients, colorectal in 21% of the patients, and urogenital system in 19% of the patients, while the disease appeared idiopathically in 36% of the patients. On the other hand, the researchers of the present study did not determine any etiological factors in 26.3% of the cases, but detected urinary tract infection in 31.5% of the patients and genitoperineal abscess in 26.3% of the patients.
Aerobic and anaerobic patients can be isolated from FG patients. Most frequently isolated microorganisms include E. coli (80%), Klebsiella pneumonia, Bacteroides, Pseudomonas, Staphylococci, and Enterobacter species.,, In the present study, the most frequently isolated microorganism was E. coli, and other isolated microorganisms were similar to the previous studies.
For FG, it is recommended to start with preoperative broad spectrum antibiotic treatment with double or triple combinations, and to continue the same treatment regime or change antibiotic type according to the result of the culture antibiogram.,
In the case of our patients, the triple empirical treatment involving ceftriaxone, ornidazole, and gentamicin was started IV after the initial evaluation, then the treatment regime was readjusted according to the result of the culture antibiogram. Frequent debridement is recommended to control the severe infection in FG patients. For all patients, either urinary catheterization or cystostomy was performed, infected tissues were debrided and the debridement procedure was repeated in case of clinical requirement. The lesion area in both groups were 211 ± 101.4 cm 2 and 96.6 ± 13.2 cm 2 in Group 1 and Group 2, respectively (P = 0.001). The infected wound was treated with hydrogen peroxide and povidone iodine. The major limitations of our study are the small sample size, and retrospective nature. These results should be supported by prospective, randomize, and large patient series.
| Conclusion|| |
Despite the contradictory series regarding the correlation between DM, which is a risk factor in FG patients, and mortality, our findings showed that the presence of DM was both a predisposing factor for FG, and also worsened the progress of the existing clinical condition. In the present study, the researchers determined that the diabetic patients with HbA1c level of 7 or higher had a worse prognosis, and increased mortality. In addition to FGSI, which was described by Laor et al. for the first time, the researchers of the present study believe that HbA1c levels can also prove to be useful to predict the mortality and morbidity rates in diabetic patients.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Corman JM, Moody JA, Aronson WJ. Fournier's gangrene in a modern surgical setting: Improved survival with aggressive management. BJU Int 1999;84:85-8.
Sorensen MD, Krieger JN, Rivara FP, Klein MB, Wessells H. Fournier's gangrene: Management and mortality predictors in a population based study. J Urol 2009;182:2742-7.
Koukouras D, Kallidonis P, Panagopoulos C, Al-Aown A, Athanasopoulos A, Rigopoulos C, et al.
Fournier's gangrene, a urologic and surgical emergency: Presentation of a multi-institutional experience with 45 cases. Urol Int 2011;86:167-72.
Ersay A, Yilmaz G, Akgun Y, Celik Y. Factors affecting mortality of Fournier's gangrene: Review of 70 patients. ANZ J Surg 2007;77:43-8.
Laor E, Palmer LS, Tolia BM, Reid RE, Winter HI. Outcome prediction in patients with Fournier's gangrene. J Urol 1995;154:89-92.
Johnin K, Nakatoh M, Kadowaki T, Kushima M, Koizumi S, Okada Y. Fournier's gangrene caused by Candida
species as the primary organism. Urology 2000;56:153xiii-153xv.
Janane A, Hajji F, Ismail TO, Chafiqui J, Ghadouane M, Ameur A, et al.
Hyperbaric oxygen therapy adjunctive to surgical debridement in management of Fournier's gangrene: Usefulness of a severity index score in predicting disease gravity and patient survival. Actas Urol Esp 2011;35:332-8.
Yilmazlar T, Ozturk E, Alsoy A, Ozguc H. Necrotizing soft tissue infections: APACHE II score, dissemination, and survival. World J Surg 2007;31:1858-62.
Fajdic J, Gotovac N, Hrgovic Z. Fournier gangrene: Our approach and patients. Urol Int 2011;87:186-91.
Eke N. Fournier's gangrene: A review of 1726 cases. Br J Surg 2000;87:718-28.
Morua AG, Lopez JA, Garcia JD, Montelongo RM, Guerra LS. Fournier's gangrene: Our experience in 5 years, bibliographic review and assessment of the Fournier's gangrene severity index. Arch Esp Urol 2009;62:532-40.
Roghmann F, von Bodman C, Löppenberg B, Hinkel A, Palisaar J, Noldus J. Is there a need for the Fournier's gangrene severity index? Comparison of scoring systems for outcome prediction in patients with Fournier's gangrene. BJU Int 2012;110:1359-65.
Verma S, Sayana A, Kala S, Rai S. Evaluation of the Utility of the Fournier's Gangrene Severity Index in the Management of Fournier's Gangrene in North India: A Multicentre Retrospective Study. J Cutan Aesthet Surg 2012;5:273-6.
Jeong HJ, Park SC, Seo IY, Rim JS. Prognostic factors in Fournier gangrene. Int J Urol 2005;12:1041-4.
Ulug M, Gedik E, Girgin S, Celen MK, Ayaz C. The evaluation of microbiology and Fournier's gangrene severity index in 27 patients. Int J Infect Dis 2009;13:e424-30.
Yeniyol CO, Suelozgen T, Arslan M, Ayder AR. Fournier's gangrene: Experience with 25 patients and use of Fournier's gangrene severity index score. Urology 2004;64:218-22.
Tuncel A, Aydin O, Tekdogan U, Nalcacioglu V, Capar Y, Atan A. Fournier's gangrene: Three years of experience with 20 patients and validity of the Fournier's Gangrene Severity Index Score. Eur Urol 2006;50:838-43.
Stephens BJ, Lathrop JC, Rice WT, Gruenberg JC. Fournier's gangrene: Historic (1764-1978) versus contemporary (1979-1988) differences in etiology and clinical importance. Am Surg 1993;59:149-54.
Unal B, Kocer B, Ozel E, Bozkurt B, Yildirim O, Altun B, et al.
Fournier gangrene. Approaches to diagnosis and treatment. Saudi Med J 2006;27:1038-43.
Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, et al.
Executive summary: Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2011;57:793-8.
Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al.
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000;321:405-12.
Atakan IH, Kaplan M, Kaya E, Aktoz T, Inci O. A life-threatening infection: Fournier's gangrene. Int Urol Nephrol 2002;34:387-92.
Yanar H, Taviloglu K, Ertekin C, Guloglu R, Zorba U, Cabioglu N, et al.
Fournier's gangrene: Risk factors and strategies for management. World J Surg 2006;30:1750-4.
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5], [Table 6]